Galmed Pharmaceuticals

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter of 2025. The company has adopted a new digital asset management strategy to enhance capital efficiency and drive shareholder value. This includes the potential allocation of up to 50% of its cash reserves, approximately $10 million, for digital asset investments. Galmed is engaging Tectona Ltd. to advise on this strategy. Additionally, Galmed terminated a previous agreement with Entomus s.r.o. for a drug delivery system, opting instead to invest up to $2 million in a new UK-based company for its development. Financially, Galmed raised $7.6 million in 2025, with increased R&D and administrative expenses contributing to a net loss of $2.5 million for the quarter.

growth-positive

Galmed Pharmaceuticals Ltd., based in Ramat Gan, Israel, reported a net income of $2.5 million for its second quarter. This translates to a net income of 63 cents per share. The financial results indicate a positive growth trajectory for the company. The report was generated by Automated Insights using data from Zacks Investment Research.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, announced a new digital asset management strategy to enhance capital efficiency and drive shareholder value. The company plans to allocate up to 50% of its cash reserves, approximately $10 million, to digital assets. Galmed is engaging Tectona Ltd. to advise and implement this strategy. Additionally, Galmed terminated a previous agreement with Entomus s.r.o. for a drug delivery system and will instead invest up to $2 million in a new UK-based company for its development. Financially, Galmed reported a net loss of $2.5 million for Q2 2025, with increased R&D and administrative expenses. The company raised $7.6 million in 2025, primarily through its ATM facility.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has approved a digital asset management strategy as part of a new treasury investment policy. The company plans to invest up to $10 million, representing about 50% of its cash reserves, in digital assets to diversify its balance sheet and enhance capital efficiency. Galmed has engaged Tectona Ltd., a specialized crypto treasury management service provider, to advise and implement this strategy. The initiative aims to leverage blockchain-based assets for growth and liquidity opportunities, optimize treasury performance, and support the companys operational and strategic needs.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, announced a new digital asset management strategy to diversify its balance sheet and enhance capital efficiency. The strategy includes investing up to $10 million, representing 50% of its cash reserves, in digital assets. Galmed has engaged Tectona Ltd. to provide advisory and operational services for managing these assets. The company also increased its authorized share capital from 50 million to 900 million ordinary shares. This move aims to provide flexibility for raising capital and pursuing strategic opportunities. The initiative reflects Galmeds proactive approach to financial management and innovation, positioning it to benefit from the digital economys growth.

growth-positive

Galmed Pharmaceuticals Ltd. announced a significant milestone in its Phase 3 ARMOR study, revealing a proprietary pharmacodynamic biomarker signature for its lead candidate, Aramchol. This discovery highlights Aramchols potential beyond liver-focused applications, indicating broader therapeutic capabilities in cardiometabolic and inflammatory conditions. The study demonstrated a reduction in systemic inflammation and cardiac stress, with a significant decrease in ANP, a marker for heart failure. Galmeds collaboration with Proteas Health, a leader in precision biomarker development, positions the company at the forefront of AI-driven biomarker-guided therapeutics. The findings are expected to support regulatory discussions and inform future trials, opening potential multi-billion-dollar market opportunities. Galmed is actively pursuing strategic partnerships and expanding its product pipeline.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, announced a significant milestone in its Phase 3 ARMOR study, revealing a proprietary pharmacodynamic biomarker signature for its lead candidate, Aramchol. This discovery highlights Aramchols potential beyond liver-focused applications, indicating broader therapeutic capabilities in cardiometabolic and inflammatory conditions. The study showed reductions in inflammation and cardiac stress, and a decrease in ANP, a marker for heart failure, suggesting potential market expansion. Galmeds strategic collaboration with Proteas Health, an AI-driven biomarker development leader, positions the company at the forefront of precision therapeutics. This advancement is expected to accelerate clinical decision-making and enhance regulatory and commercial success.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, reported its financial results for Q1 2025 and announced significant developments. The company revealed first-time results in oncology studies, showing that Aramchol significantly enhances Bayers Regorafenib effect in GI cancer models. Galmed also signed a term sheet for developing a novel Semaglutide sublingual formulation. The company raised $6.5 million since the beginning of 2025, bringing its current cash balance to $20.1 million. The financial summary indicates a net loss of $1.1 million for Q1 2025, a decrease from the previous year. Galmed is focused on expanding its product pipeline targeting cardiometabolic indications and other innovative product candidates.

growth-negative

Galmed Pharmaceuticals Ltd., based in Ramat Gan, Israel, reported a financial loss of $1.1 million for the first quarter. The loss translates to 62 cents per share. This financial report was generated using data from Zacks Investment Research and highlights a negative financial performance for the company in the first quarter. The article does not mention any new partnerships, investments, or acquisitions, nor does it discuss any changes in management or layoffs.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, reported financial results for Q1 2025 and recent developments. The company announced positive results in oncology studies, showing that Aramchol enhances Bayers Regorafenib effect in GI cancer models. Galmed signed a term sheet for developing a novel semaglutide sublingual formulation and raised $6.5 million since the start of 2025, with a current cash balance of $20.1 million. Financial performance showed a net loss of $1.1 million for Q1 2025, a decrease from the previous year. The company is focused on developing Aramchol for liver disease and expanding its pipeline to include cardiometabolic indications.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, announced significant pre-clinical results for its drug Aramchol, an SCD1 inhibitor. Aramchol demonstrated effectiveness in attenuating and preventing biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC). The drug significantly inhibited TGFβ-induced hepatic fibrosis pathways and upregulated PPAR signaling. These findings support further clinical studies of Aramchol in patients with fibrosis-driven liver cancers. The results are promising for addressing conditions like PSC and primary biliary cholangitis, which are characterized by cholestatic injury and fibrosis. The study highlights Aramchols potential in improving outcomes for liver fibrosis and related cancers.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, announced promising results for its drug Aramchol in pre-clinical models of primary sclerosing cholangitis (PSC). Aramchol, an SCD-1 inhibitor, demonstrated significant anti-fibrotic effects in mouse models, reducing fibrotic markers and inhibiting hepatic fibrosis pathways. These findings support further clinical studies of Aramchol for treating biliary fibrosis and hepatic cancers like cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). The company aims to transition to Phase 2/3 clinical studies for gastrointestinal oncology indications. Galmed is also exploring opportunities to expand its product pipeline targeting cardiometabolic indications. The article highlights the potential of Aramchol in addressing unmet medical needs in liver diseases.

growth-positive

The article highlights a surge in interest for several biotech companies, including Galmed Pharmaceuticals, which is focused on developing Aramchol for liver and fibro-inflammatory diseases. Galmed is currently in the clinical stage, working on treatments for noncirrhotic nonalcoholic steatohepatitis (NASH) and exploring other indications. Other companies mentioned include Protagenic Therapeutics, Hepion Pharmaceuticals, Rigel Pharmaceuticals, and Bolt Biotherapeutics, all of which are in various stages of developing treatments for conditions like cancer and liver diseases. The article suggests a positive outlook for these companies due to their innovative approaches and ongoing clinical trials.

growth-positive

Galmed Pharmaceuticals Ltd. announced promising results from studies showing that their drug Aramchol, when combined with Bayers Regorafenib, significantly reduces hepatic tumor growth in mice models. The combination enhances autophagy and death receptor signaling, leading to increased tumor cell death. A Phase 1b clinical trial is planned for Q4 2025 at VCUs Massey Cancer Center. This development is part of Galmeds broader strategy to advance its oncology program alongside its Semaglutide GLP-1 development. The study highlights the potential of Aramchol to overcome therapy resistance in liver and colorectal cancers, positioning the combination as a cost-effective first-line treatment.

growth-positive

Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases. Their lead product, nebokitug, is a monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation. Nebokitug has shown promise in clinical trials, demonstrating a favorable safety profile and potential to treat severe fibro-inflammatory diseases. The company is preparing for a Phase 3 trial for primary sclerosing cholangitis (PSC), following positive Phase 2 results. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. This article highlights the growth potential of Chemomab Therapeutics, as well as other biotech companies experiencing increased interest.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has signed a binding term-sheet with Entomus s.r.o. for a license agreement to develop and commercialize a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation. This formulation allows the absorption of sublingually administered peptides such as GLP-1, offering a non-invasive alternative to injectable and oral forms. The agreement is expected to be finalized within 90 days, detailing milestone and royalty payments. The GLP-1 market is projected to grow significantly, with Jefferies estimating it to reach over $120 billion by 2030. This partnership positions Galmed to capitalize on the growing demand for GLP-1 therapies, especially in markets with high rates of type 2 diabetes and obesity.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has signed a binding term-sheet with Entomus s.r.o. for a license agreement to develop and commercialize a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation. This formulation allows sublingual administration of peptides like GLP-1, offering a non-invasive alternative to injectable and oral forms. The agreement aims to enhance the bioavailability of semaglutide, potentially improving patient compliance and reducing side effects. The GLP-1 market is projected to grow significantly, and Galmed plans to initially target countries with expiring patents. The company is focused on expanding its product pipeline in cardiometabolic indications.

growth-positive

Galmed Pharmaceuticals has entered into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to study the effects of Aramchol, an SCD1 inhibitor, in overcoming drug resistance in gastrointestinal cancers. This collaboration aims to explore Aramchols potential in combination with standard therapies for colorectal and liver cancers, addressing a significant unmet need in cancer treatment. The initiative is part of Galmeds strategic expansion into oncology, leveraging recent findings on lipid metabolisms role in drug resistance. The project seeks to reprogram tumor metabolism and enhance the efficacy of existing treatments, potentially offering a breakthrough for patients with limited options.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has unveiled new pharmacodynamic blood markers for its lead compound, Aramchol, in collaboration with Proteas Health. The analysis from the Phase 3 ARMOR MASH study shows that Aramchol treatment decreases markers of chronic systemic inflammation, oxidative stress, and atherosclerotic plaque pathogenesis. The findings also indicate a reduction in ANP, a marker for heart failure, and suggest potential expansion into additional cardiometabolic and oncological indications. The use of proteomics and AI technologies has been pivotal in identifying these biomarkers, highlighting Aramchols broader therapeutic relevance.

growth-positive

Galmed Pharmaceuticals Ltd. announced positive preliminary results from Part 1 of the Phase 1 Bioavailability AM-001 Study of Aramchol Meglumine, an improved formulation of its lead compound. The study, conducted in response to an FDA request, aims to compare the bioavailability of Aramchol Meglumine to Aramchol acid. The results show that Aramchol Meglumine offers higher bioavailability, with a 400 mg dose achieving nearly double the area under the curve compared to Aramchol acid. The optimal dose for future trials is identified as 200 mg once daily, which is expected to improve patient compliance and reduce manufacturing costs. Aramchol Meglumine is protected by patents until 2035 and has received FDA approval for transition from Aramchol acid.

growth-negative

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the SEC. The company is focused on developing Aramchol for oncological indications outside of liver disease and is actively seeking to expand its product pipeline. The report highlights various risks and uncertainties, including regulatory challenges, market conditions, and competition, that could impact the companys future performance. Galmed is in the clinical trial stage for its product Aramchol and is facing intense competition and potential intellectual property issues. The company has not yet received FDA approval for its products.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, announced the grant of a new patent for its lead compound, Aramchol, in combination with Resmetirom for treating non-alcoholic steatohepatitis (NASH) and liver fibrosis. This patent extends Aramchols market exclusivity through September 2039, positioning Galmed to capitalize on the growing NASH treatment market, projected to reach over $48 billion by 2035. The patent comes as the industry shifts towards combination therapies for NASH, a complex disease with multiple pathologies. Aramchols unique mechanism and anti-fibrotic efficacy make it a promising candidate for combination regimens, aiming to place Galmed at the forefront of next-generation NASH therapies.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, announced the grant of a new patent for its lead compound, Aramchol, in combination with Resmetirom for treating non-alcoholic steatohepatitis (NASH) and liver fibrosis. This patent extends Aramchols market exclusivity until September 2039, positioning Galmed to capitalize on the growing NASH treatment market. The patent supports Galmeds strategy of using combination therapies to address the complex pathogenesis of NASH. Aramchol, a first-in-class SCD1 modulator, has shown promising anti-fibrotic effects in clinical trials. The patent strengthens Galmeds intellectual property portfolio, enhancing its strategic flexibility and potential for future commercialization.

growth-negative

Galmed Pharmaceuticals Ltd., based in Ramat Gan, Israel, reported a financial loss of $1.9 million for its third quarter. The loss translates to $2.31 per share. This report was generated using data from Zacks Investment Research and highlights the companys financial challenges during this period. The article does not mention any new partnerships, acquisitions, or changes in management, focusing solely on the companys financial performance.

growth-positive

Galmed Pharmaceuticals Ltd. announced the publication of one-year results from the Open-Label part of its global Phase 3 trial of Aramchol in patients with NASH and fibrosis in the journal Hepatology. The study showed significant anti-fibrotic effects of Aramchol 300mg BID, confirmed through multiple objective measurements including AI digital analysis. The publication highlights the potential of Aramchol as a therapeutic option for MASH and fibrosis, positioning it as a potent anti-fibrotic compound. The study involved collaboration with several experts and institutions, emphasizing the scientific communitys interest in this innovative treatment.

growth-positive

Galmed Pharmaceuticals Ltd. announced plans to broaden its drug development activities based on recent scientific findings and an extended cash runway. The company raised $7.5 million through warrant exercises and equity line drawdowns. Galmed will expand into two new programs targeting resistance to standard oncological treatments and cardiac fibrosis. The company aims to release new data from these programs by Q4 2024. Recent studies highlight the potential of SCD1 inhibition in treating cardiometabolic diseases and preventing drug resistance in cancer treatments. Galmed is collaborating with academia and industry to accelerate development using advanced methodologies.

growth-positive

The article discusses three penny stocks with strong buy ratings for April 2024. These include Galmed Pharmaceuticals, which is focused on developing therapies for liver diseases, Selina Hospitality, which caters to the remote working and digital nomad crowd, and TRACON Pharma, which develops targeted therapies for cancer, wet age-related macular degeneration, and fibrotic diseases. All three companies have been given strong buy ratings by analysts, indicating significant growth potential. Selina Hospitality recently received a strategic investment of $10 million from Global University Systems.

Neutral

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (SEC). The report is available on the SECs website and Galmeds Investor Relations website. The company is focused on the development of Aramchol for liver and fibro-inflammatory diseases and is collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.

growth-negative

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has filed its Annual Report for the fiscal year ended December 31, 2023. The company is focused on developing Aramchol for liver and fibro-inflammatory diseases, specifically targeting NASH and PSC. They are also collaborating with Hebrew University on Amilo-5MER. The report highlights the companys ongoing clinical trials, regulatory challenges, and financial uncertainties. Additionally, geopolitical instability in the Middle East poses potential risks to their operations. The company has not yet received FDA approval for its products and faces intense competition in the biopharmaceutical industry. The report emphasizes the inherent risks and uncertainties in forward-looking statements, urging caution in relying on them.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has been granted a European patent for the use of a combination of Aramchol and Resmetirom for the treatment of NASH/MASH and liver fibrosis. The patent has been granted in France, Germany, Italy, the Netherlands, and the United Kingdom, with approval pending in the United States and other countries. This strengthens and extends the patent protection of its lead compound, Aramchol, until September 2039. Galmed believes that the optimum treatment for NASH/MASH will be combination therapy, and this new patent reflects that belief.

Growth-Positive

The article discusses the pre-market stock movers worth watching. Companies like Tracon Pharmaceuticals, LQR House, Mountain Crest Acquisition, Connect Biopharma, Symbotic, Marpai, Invo Bioscience, Mobiv Acquisition, Renalytix, and Artivion are seeing positive growth due to various reasons such as collaboration agreements, merger plans, earnings, public share offerings, etc. On the other hand, companies like Reliance Global, MorphoSys, Sibanye Stillwater, Alzamend Neuro, Nogin, Galmed Pharmaceuticals, AgileThought, Bruush Oral Care, Vicarious Surgical, and Acutus Medical are experiencing a decrease in their stock prices.

Growth-Negative

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has announced a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study due to unexpected events on October 7th. The company had planned to complete a Ph1 pharmacokinetic (PK) study before the initiation of the Ph 2a study. However, the disruption caused by the attack of Hamas has resulted in a delay in the original planned timelines. The new time estimates depend on timelines established by Galmeds US and European partners and vendors.

growth-negative

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, announced a delay of 6-9 months in the initiation of its Phase 2a study for Primary Sclerosing Cholangitis (PSC) due to disruptions caused by the Hamas attack on October 7th. The company had planned to start the study in the last quarter of 2023, following a Phase 1 pharmacokinetic study. The delay is attributed to the impact of the attack and the subsequent declaration of war by Israel, affecting timelines with US and European partners and vendors. Galmed is working to mitigate these delays and aims to resume full activity. The company is focused on developing Aramchol for liver and fibro-inflammatory diseases and is collaborating with the Hebrew University on another project.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has announced the allowance of a Japanese patent related to the treatment of pulmonary and dermal fibrosis. The company has already been granted a similar patent in Mexico, and approval in the US and the rest of the world is pending. The patent strengthens the protection of Galmeds lead compound, Aramchol, until November 2037. The company previously reported significant anti-fibrotic effects of Aramchol in a pre-clinical model of lung fibrosis.

Growth-Negative

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has received a letter from the Nasdaq Listing Qualifications stating that the company is not in compliance with the minimum bid price requirement for continued listing. The company has a compliance period of 180 calendar days, from September 18, 2023, to March 18, 2024, to regain compliance. If the company fails to demonstrate compliance by the end of the 180-day period, its ordinary shares may be subject to delisting. The letter has no immediate effect on the companys Nasdaq listing or the trading of its ordinary shares.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has announced that it has entered into securities purchase agreements with two institutional investors. The investors will purchase 5,600,000 of Galmeds ordinary shares and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant. The gross proceeds of the Offering to the Company are expected to be approximately $7.0 million. The Offering is expected to close on or about July 18, 2023.

Growth-Positive

Galmed Pharmaceuticals Ltd. has announced a strategic partnership with OnKai, which will apply its artificial intelligence (AI) models for enrollment and execution of clinical trials in underserved communities. The partnership will begin with Galmeds innovative Primary Sclerosing Cholangitis (PSC) clinical development program. OnKais innovative planning tool will generate a comprehensive enrollment plan for each trial phase, integrating underserved communities in clinical studies. The collaboration is expected to foster mutual benefits between Galmed, its principal sites, and the relevant clinics in underserved communities.

growth-negative

Galmed Pharmaceuticals reported its financial results for the first quarter of 2023. The company also announced several recent developments, including the initiation of a new clinical program for the treatment of Primary Sclerosing Cholangitis (PSC) and a strategic partnership with Onkai, Inc. Galmed is discontinuing its evaluation of strategic alternatives and has regained compliance with the Nasdaq minimum bid price rule. The financial summary shows a decrease in net loss and research and development expenses compared to the same period last year. The companys cash and cash equivalents decreased from $13.8 million to $12.2 million. Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases.

growth-positive

Galmed Pharmaceuticals has announced the initiation of a new clinical program to evaluate its lead compound, Aramchol meglumine, for the treatment of Primary Sclerosing Cholangitis (PSC). PSC is a rare liver disease with no approved treatment. Galmed plans to conduct a Phase 2 study in the last quarter of 2023 to evaluate the effects of Aramchol meglumine in patients with PSC. The study will be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University. The company expects the study to provide insights into the translatability of preclinical data on the utility of Aramchol in humans with PSC. Galmed believes that Aramchol has a promising clinical potential in patients with PSC and looks forward to the first clinical data in 2024.

growth-positive

Galmed Pharmaceuticals Ltd. has announced a $3M equity investment in OnKai Inc., leading a $6M investment round. The investment gives Galmed a strategic minority stake in OnKai. The companies are also entering into a strategic partnership agreement to leverage their complementary knowledge and experience. OnKai is a US-based technology company that has developed an AI-powered digital platform to facilitate health equity in underserved communities across the US. The platform could potentially enable 80M underserved patients to participate in clinical trials. Galmed plans to use the platform to improve the planning and execution of its upcoming clinical trials.

Neutral

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (SEC). The report is available on the SECs website and Galmeds Investor Relations website. The company is focused on the development of Aramchol for the treatment of liver disease and is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.

growth-positive

Galmed Pharmaceuticals has been granted a new patent by the United States Patent and Trademark Office (USPTO) for its drug Aramchol, extending its exclusivity until December 2034. The patent provides protection for Aramchol per se and its use in the treatment of NASH and Fibrosis. This strengthens Galmeds patent portfolio and enhances the potential commercial horizon for Aramchol. The companys research and development platform has produced over 20 issued patents. Galmed is currently investigating the therapeutic potential of Aramchol in various anti-fibrotic indications.

growth-positive

Galmed Pharmaceuticals reported full results from the Open-Label Part of the ARMOR study, showing the positive effects of Aramchol in treating NASH and liver fibrosis. The study demonstrated histological improvement in fibrosis, reduction in liver stiffness, and reduction in biochemical markers of liver injury. Galmed is submitting the data to the FDA and seeking partnering opportunities for Aramchols clinical development. The company has a good safety profile and is considering incorporating more sensitive histology reading methodologies in future NASH clinical studies. The Double-Blind part of the ARMOR study has not yet been initiated. Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on liver, metabolic, and inflammatory diseases.

growth-negative

Galmed Pharmaceuticals has received a letter from The Nasdaq Stock Market notifying the company that it is eligible for an additional 180-day period to regain compliance with the Nasdaqs minimum $1 bid price per share requirement. The company failed to maintain the minimum bid price and did not regain compliance during the initial 180-day period. If the bid price closes at or above $1 per share for 10 consecutive trading days before June 12, 2023, the company will regain compliance. Galmed Pharmaceuticals is a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER.

growth-negative

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has provided a business update and reported financial results for the second quarter of 2022. The company has discontinued the Open Label Part of the ARMOR study and is refocusing its research and development on advancing Aramchol for new anti-fibrotic indications. They have also implemented a cost reduction plan, including layoffs and discontinuing non-essential research and development activities. Galmed is evaluating the continuation of the development of Aramchol and Amilo-5MER and exploring strategic alternatives to optimize resources and enhance shareholder value. In terms of financials, the companys cash and cash equivalents, restricted cash, and marketable debt securities totaled $22.5 million as of June 30, 2022, compared to $34.9 million at the end of 2021. Galmed reported a net loss of $3.7 million for the second quarter of 2022. The company is focused on the development of Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis (NASH), fibrosis, and other fibrotic indications.

growth-positive

Endo Internationals subsidiary, Endo Ventures Limited, has partnered with Quoin Pharmaceuticals for the development and distribution of Quoins pipeline candidate, QRX003, in Canada. QRX003 is being developed for the treatment of Netherton syndrome, a rare skin disorder. Endos operating company, Paladin Labs Inc., will handle all commercial activities related to QRX003 in Canada, with plans to launch in 2025. Meanwhile, Endo is facing financial troubles, with ongoing litigation over opioid sales and negotiations for restructuring over $8 billion of debt. There are suggestions for the company to file for bankruptcy.

growth-positive

Galmed Pharmaceuticals announced significant effects of Aramchol in pre-clinical models of lung and gastrointestinal fibrosis. Aramchol demonstrated anti-fibrotic activity and resulted in statistically significant fibrosis improvement in lung fibrosis and inflammatory bowel disease models. The findings suggest that Aramchol may have potential in treating fibrosis in various organs. Galmed Pharmaceuticals is currently assessing Aramchols anti-fibrotic effects in kidney and skin. The company aims to transition to Phase 2/3 clinical studies with Aramchol in indications with unmet need and faster development pathways.

growth-positive

Galmed Pharmaceuticals Ltd. has announced that the United States Patent and Trademark Office (USPTO) has granted the company new patents related to the use of its lead compound, Aramchol, for the treatment of fibrosis and for modulating gut microbiota. An additional patent grant protects the low dose composition of Aramchol salt until June 8, 2036. With these patents, Galmed is extending the IP protection of Aramchol until December 2038. The company is currently in a Phase 3 clinical trial for the treatment of NASH and fibrosis.

growth-positive

Galmed Pharmaceuticals, based in Tel Aviv, has announced positive results from the Phase 3 study of its drug Aramchol for treating fatty liver disease. The study showed that fibrosis progressed less in 15 out of 16 patients enrolled, with half of the patients seeing their fibrosis go back a stage. Galmed has attracted significant investment for the development of the drug, raising $18.4 million in February. The company plans to start a 1,000-patient double-blind study next year and hopes to receive FDA approval for Aramchol in 2024.

growth-positive

Tel Aviv-based Galmed Pharmaceuticals Ltd. has raised $18.4 million in capital to further develop its flagship drug, Aramchol, which is used to treat fatty liver disease. The company raised $8.4 million through an IPO and an additional $10 million through a public offering of shares. The new capital will also be used to advance the development of Amilo-5MER for the treatment of autoimmune diseases. Galmed Pharmaceuticals is currently conducting a Phase 3 clinical trial for Aramchol in 200 medical centers across 18 countries. The company plans to publish preliminary results of the trial in the fourth quarter of this year.

growth-positive

Galmed Pharmaceuticals announced the upcoming publication of a paper describing the role of SCD1 in hepatic fibrogenesis and the anti-fibrotic effect of Aramchol. The paper reinforces Aramchols potential efficacy in NASH patients with fibrosis. Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on liver, metabolic, and inflammatory diseases.

growth-positive

Galmed Pharmaceuticals has announced the addition of an open-label part to its ARMOR Phase 3 registrational study for Aramchol, a treatment for nonalcoholic steatohepatitis (NASH) and fibrosis. The open-label part will evaluate treatment response kinetics, pharmacokinetics, and safety of Aramchol in approximately 150 subjects. Galmed is also developing a new product, Aramchol meglumine, which has shown similar results to Aramchol acid in a Phase 1 study. The company plans to submit the results to the FDA and discuss introducing Aramchol meglumine into the ARMOR Phase 3 study. The addition of the open-label part and the development of Aramchol meglumine are part of Galmeds strategy to optimize its clinical development program. The company expects to enroll the first patients in the open-label part in Q1 2021 and report the first histology data by Q4 2021.

growth-positive

Galmed Pharmaceuticals and MyBiotics Pharma have entered into a research and development collaboration agreement to identify and optimize the selected microbiome repertoire associated with the response to Aramchol. The collaboration aims to develop a standalone microbiome-based treatment for non-alcoholic steatohepatitis (NASH) and fibrosis. MyBiotics will use its proprietary SuperDonor technology and computational AI platform to identify and optimize consortia of bacteria to enhance Aramchols clinical efficacy and response rate. The collaboration also aims to identify specific microbial biomarkers for Aramchol based on macrobiome data collected from Galmeds clinical studies. The partnership is part of Galmeds plan to maximize Aramchols clinical efficacy and establish itself in the microbiome NASH therapeutic development space.

growth-positive

Gannex Pharma Co., Ltd. and Galmed Pharmaceuticals have entered into a research agreement for combination therapy of ASC41 and Aramchol for the treatment of non-alcoholic steatohepatitis (NASH). ASC41 is an oral thyroid hormone receptor beta (THR-beta) agonist, while Aramchol is a synthetic small molecule that inhibits SCD 1 expression. The combination therapy aims to address the multiple liver pathologies associated with NASH. The financial details of the transaction were not disclosed.

growth-positive

Galmed Pharmaceuticals has provided an update on its pipeline program, specifically on the development of Amilo-5MER, a synthetic peptide for the treatment of chronic inflammatory diseases. Amilo-5MER has shown promising results in reducing chronic inflammation in animal models and has the potential to be used in the treatment of severe COVID-19 cases. Galmed plans to submit an IND in Q4 2020 and initiate a Phase 1 study in the UK. If successful, Galmed will exercise its option to receive an exclusive license to the Amilo-5MER technology. The company is focused on liver, metabolic, and immune diseases, with its lead compound Aramchol currently in Phase 3 trials for the treatment of NASH and fibrosis.

growth-positive

Galmed Pharmaceuticals has completed its End-of-Phase 2 meeting with the FDA and reached general agreement on key aspects of the Phase 3/4 development and registration plan for Aramchol, its oral therapy for the treatment of NASH and fibrosis. The company plans to submit its study protocol and other design elements of its ARMOR trial to the FDA in the coming weeks, with study commencement expected in the third quarter of 2019. Galmed plans to present an overview of its development plan at the NASH Summit in Boston on April 24, 2019.

growth-positive

Galmed Pharmaceuticals Ltd., a clinical-stage company based in Israel, is planning to raise $75 million in an underwritten offering of public shares. The proceeds will be used for clinical and business development as well as general corporate purposes. The companys stock has seen a significant increase of around 125% over the past two weeks following the announcement of a successful study on June 11.

growth-positive

Galmed Pharmaceuticals Ltd. has raised $6 million in a secondary offering on Nasdaq. The company is developing a drug for treating inflammation of the liver caused by fatty-liver disease. The offering was conducted at $6 per share with a free share attached. The share price jumped 15.08% on Nasdaq to $5.80, giving a market cap of $83.94 million. Galmed expects the results of a much bigger clinical trial on fatty liver treatment in the coming months.

growth-positive

Galmed Pharmaceuticals saw a 47% increase in share price after the acquisition of Nimbus by Gilead Biotech for $78 million. Galmed is developing a treatment for fatty liver disease and is in advanced efficacy trials. The company had a market cap of $81.4 million after the rise in share price.

growth-positive

Galmed Pharmaceuticals, headquartered in Tel Aviv and New York, is developing a drug candidate called Aramchol to treat non-alcoholic steato-hepatitis (NASH), a severe form of fatty liver disease. The company is currently advancing towards its Phase IIb study, which involves 240 NASH patients in nine countries. Galmed has received pre-approved fast-track designation from the US FDA and clearance from regulatory agencies in the UK, Germany, and France. Galmed is one of four companies conducting advanced clinical studies for NASH treatment. The Seeking Alpha online platform considers Aramchol a potential acquisition candidate. Galmed raised $44 million in its initial public offering on NASDAQ. The IPO proceeds will support the company until the completion of the multicenter study in 2017.

growth-positive

Galmed Pharmaceuticals Ltd., a Tel Aviv-based biopharmaceutical company, has announced the pricing of its Nasdaq IPO. The company aims to raise $35 million at a company valuation of $132 million by issuing 2,837,400 ordinary shares at a price of $13.50 per share. Galmed, which is developing a treatment for fatty liver disease and cholesterol gallstones, plans to begin the Phase IIb clinical trial on 240 patients in the second half of 2014. The company is owned by CEO Allen Baharaff, with a 53% stake, and other investors.

growth-positive

Galmed Pharmaceuticals is planning to raise tens of millions of dollars on Nasdaq through an IPO in December. The company is developing a treatment for fatty liver disease and has already conducted a successful Phase I clinical trial. Galmed is racing against two other companies in the Phase II stage, after Roche Holdings and Gilead Sciences terminated their trials. The Phase II study, which will include 120 patients, is due to begin in a few months. Galmed plans to conduct a Phase III clinical trial with a big pharma partner, but may go it alone if the IPO is successful.